Gastroesophageal Reflux Disease Therapeutics Market Trends, Demand, Insights: 2024-2033

Global gastroesophageal reflux disease therapeutics market size is expected to reach $7.33 Bn by 2028 at a rate of 5.1%, segmented as by type, branded, generic

Share this Post to earn Money ( Upto ₹100 per 1000 Views )


Gastroesophageal Reflux Disease Therapeutics Market Trends, Demand, Insights: 2024-2033
Gastroesophageal Reflux Disease Therapeutics Market Trends, Demand, Insights: 2024-2033

Overview and Scope

Gastroesophageal reflux disease (GERD) therapeutics is a medication for chronic medical illness characterized by the upward movement of stomach contents into the esophagus that causes heartburn and regurgitation. The therapeutics are used to neutralize and reduce the production of stomach acid to maintain optimal pH in the gut and prevent the passage of fluids back into the stomach that cause acid reflux.

Sizing and Forecast

The gastroesophageal reflux disease therapeutics market size has grown steadily in recent years. It will grow from $5.78 billion in 2023 to $6 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%.  The  growth in the historic period can be attributed to changing lifestyles and dietary habits, aging population, increased awareness and diagnosis, prevailing stressful lifestyles, rise in obesity rates..

The gastroesophageal reflux disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $7.33 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%.  The growth in the forecast period can be attributed to rise in demand for novel therapies, growing geriatric population, personalized medicine approaches, focus on non-pharmacological interventions, emergence of biologics and innovative therapies.. Major trends in the forecast period include alternative therapies and mind-body practices, expanded research into gut health, advent of patient-centric care models, targeted marketing for gerd awareness, integration of digital health tools..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report 

Segmentation & Regional Insights

The gastroesophageal reflux disease therapeutics market covered in this report is segmented –

1) By Type: Branded, Generic

2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class

3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Supermarkets

4) By Application: Crohn’s Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis

North America  was the largest region in the gastroesophageal reflux disease therapeutics market in 2023. Asia-Pacific  is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East,  Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12058&type=smp 

Major Driver Impacting Market Growth

The prevalence of gastroesophageal reflux disease is expected to propel the growth of the gastroesophageal reflux disease therapeutics market moving forward. Gastroesophageal reflux disease is a chronic condition characterized by the backflow of stomach acid into the esophagus, causing symptoms such as heartburn, regurgitation, and potential complications. The gastroesophageal reflux disease (GERD) therapeutics help in reducing and managing the symptoms of acid reflux by neutralizing the pH of the gut, controlling inflammation, and improving esophageal function. For instance, in September 2022, according to the article published by WebMed, a US-based online publisher of news and information about human health, more than 60 million American adults suffer heartburn at least once a month, and more than 15 million suffer daily. Furthermore, in July 2022, statistics shared by the National Library of Medicine, a US-based federal medical library, GERD is one of the most often diagnosed digestive illnesses in the United States, with a 20% prevalence, resulting in a significant economic burden in direct and indirect expenditures as well as a negative impact on quality of life. Therefore, the prevalence of gastroesophageal reflux disease is expected to drive the growth of the gastroesophageal reflux disease therapeutics market.

Key Industry Players

Major companies operating in the gastroesophageal reflux disease therapeutics market report are Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories Ltd., Bruker Corp, Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Addex Pharmacetuicals.

The gastroesophageal reflux disease therapeutics market report table of contents includes:

  1. Executive Summary
  2. Gastroesophageal Reflux Disease Therapeutics Market Characteristics
  3. Gastroesophageal Reflux Disease Therapeutics Market Trends And Strategies
  4. Gastroesophageal Reflux Disease Therapeutics Market - Macro Economic Scenario
  5. Global Gastroesophageal Reflux Disease Therapeutics Market Size and Growth

.

.

.

  1. Global Gastroesophageal Reflux Disease Therapeutics Market Competitive Benchmarking
  2. Global Gastroesophageal Reflux Disease Therapeutics Market Competitive Dashboard
  3. Key Mergers And Acquisitions In The Gastroesophageal Reflux Disease Therapeutics Market
  4. Gastroesophageal Reflux Disease Therapeutics Market Future Outlook and Potential Analysis
  5. Appendix

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info 

 

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company  

Twitter: https://twitter.com/tbrc_info  

Facebook: https://www.facebook.com/TheBusinessResearchCompany  

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ  

Blog: https://blog.tbrc.info/  

Healthcare Blog: https://healthcareresearchreports.com/  

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model